本刊稿约论文模板电子书
首页 > 过刊浏览>2025年第卷第3期 >418-425. DOI:10.7655/NYDXBNSN240736
PDF HTML阅读 XML下载 导出引用 引用提醒
U2snRNP：肿瘤发生发展中的关键介质
作者:
作者单位:

长沙医学院医学检验学院临床生化教研室，湖南 长沙 410219

中图分类号:

R730.2

基金项目:

湖南省教育厅重点项目（23A0660）


U2 snRNP：a key mediator in tumorigenesis and development
Author:
Affiliation:

Department of Clinical Biochemistry，College of Clinical Laboratory，Changsha Medical University，Changsha 410219 ，China

  • 摘要
    • | |
  • 访问统计
    • |
  • 参考文献 [38]
    • |
  • 相似文献
    • | | |
  • 文章评论
    摘要:

    U2 小核糖核蛋白（small ribonucleoprotein，snRNP）是一种在人体细胞核剪切过程中发挥关键作用的剪接体。 mRNA的成熟，包括5′和3′末端的加工、剪接和转运，都与U2 snRNP密切相关。在剪接体组装中，U2 snRNP对内含子分支位点序列进行识别。在机体内U2 snRNP维持了人体内必需修复因子的转录。另外其可防止转录位点形成R环结构并直接促进 DNA修复。研究表明，U2 snRNP在多种人类肿瘤组织中存在，并且其主要特征是核心成分基因的突变和核心组分的表达水平升高。这些变化进一步影响了肿瘤细胞的迁移、增殖、侵袭等，是肿瘤发生发展的关键因素。鉴于U2 snRNP在肿瘤中的分子调控作用，其有望成为临床诊治和药物治疗的新靶点。文章旨在全面回顾U2 snRNP在癌症中的作用机制。

    Abstract:

    U2 small ribonucleoprotein（snRNP）is a kind of splicing body that plays a key role in the process of human nuclear splicing. The maturation of mRNA，including the processing，splicing and transport of 5′ and 3′ ends，is closely related to U2 snRNP. The intron branching site sequence is identified by U2 snRNP in splice assembly. U2 snRNP maintains the transcription of essential repair factors in the body. In addition，it can prevent the transcriptional site from forming R-loop structure and directly promote DNA repair. Studies have shown that U2 snRNP exists in a variety of human cancer tissues，and its main feature is the mutation of its core component gene and the increased expression level of core component. These changes further affect the migration，proliferation， invasion and other cellular behaviors of tumor cells，and are the key factors in the occurrence and development of tumor. In view of the molecular regulatory role of U2 snRNP in tumors，it is expected to become a new target for clinical diagnosis，treatment and drug therapy. The purpose of this article is to comprehensively review the mechanism of U2 snRNP in cancer.

    参考文献
    [1] NILSEN T W，GRAVELEY B R.Expansion of the eukaryotic proteomeby alternative splicing[J].Nature，2010，463（7280）：457-463
    [2] 田彬，杨兵，马星宇，等.肿瘤U1 snRNA蛋白互作图谱及特征分析[J].岭南现代临床外科，2023，23（2）：180-189.TIAN B，YANG B，MA X Y，et al.Tumor U1 snRNA protein interaction map and characteristic analysis[J].Ling-nan Modern Clinics in Surgury，2023，23（2）：180-189
    [3] YANG F H，BIAN T，ZHAN X C，et al.Mechanisms of the RNA helicases DDX42 and DDX46 in human U2 snRNP assembly[J].Nat Commun，2023，14（1）：897
    [4] BROSI R，HAURI H，KRAMER A.Separation of splicing factor SF3 into two components and purification of SF3a activity[J].J Biol Chem，1993，268（23）：17626-17640
    [5] KRAMER A，GRUTER P，GRONING K，et al.Combined biochemical and electron microscopic analyses reveal the architecture of the mammalian U2 snRNP[J].J Cell Biol，1999，145（7）：1355-1368
    [6] VAN DER FELTZ C，HOSKINS A A.Structural and functional modularity of the U2 snRNP in pre⁃mRNA splicing[J].Crit Rev Biochem Mol Biol，2019，54（5）：443-465
    [7] CILLONI D，ITRI F，BONUOMO V，et al.SF3B1 mutations in hematological malignancies[J].Cancers，2022，14（19）：4927
    [8] TIAN J，LIU Y P，ZHU B B，et al.SF3A1 and pancreatic cancer：new evidence for the association of the spliceo-some and cancer[J].Oncotarget，2015，6（35）：37750-37757
    [9] ZHENG Y，XUE M，SHEN H，et al.PHF5A epigenetically inhibits apoptosis to promote breast cancer progression[J].Cancer Res，2018，78：3190-3206
    [10] CHEN S S，BENBARCHE S，ABDEL⁃WAHAB O.Splicing factor mutations in hematologic malignancies[J].Blood，2021，138（8）：599-612
    [11] SIMMLER P，IOANNIDI E I，MENGIS T，et al.Mutant SF3B1 promotes malignancy in PDAC[J].Elife，2023，12：e80683
    [12] HINTZSCHE J D，GORDEN N T，AMATO C M，et al.Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma[J].Melanoma Res，2017，27（3）：189-199
    [13] NAMEKI N，TAKIZAWA M，SUZUKI T，et al.Structural basis for the interaction between the first SURP domain of the SF3A1 subunit in U2 snRNP and the human splicing factor SF1[J].Protein Sci，2022，31（10）：e4437
    [14] STANLEY R F，ABDEL ⁃WAHAB O.Dysregulation and therapeutic targeting of RNA splicing in cancer[J].Nat Cancer，2022，3（5）：536-546
    [15] HU Z，WU C，SHI Y，et al.A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese[J].Nature genetics，2011，43：792-796
    [16] BROOKS A N，CHOI P S，DEWAAL L，et al.A pan⁃cancer analysis of transcriptomechanges associated with somatic mutations in U2AF1 reveals commonly altered splicing events[J].PLoS One，2014，9：e87361
    [17] OKEYO⁃OWUOR T，WHITE B S，CHATRIKHI R，et al.U2AF1 mutations alter sequence specificity of pre⁃mRNA binding and splicing[J].Leukemia，2015，29：909-917
    [18] TENG T，TSAI J H，PUYANG X L，et al.Splicing modulators act at the branch point adenosine binding pocket defined by the PHF5A-SF3b complex[J].Nat Commun，2017，8：15522
    [19] LI J，YU B，DENG P，et al.KDM3 epigenetically controls tumorigenic potentials of human colorectal cancer stem cells through Wnt/β⁃catenin signalling[J].Nat Commun，2017，8：15146
    [20] CHANG Y，ZHAO Y L，WANG L Y，et al.PHF5A promotes colorectal cancerprogression by alternative splicing of TEAD2[J].Mol Ther Nucleic Acids，2021，26：1215-1227
    [21] YU H，LIN L B，ZHANG Z Q，et al.Targeting NF ⁃ κB pathway for the therapy of diseases：mechanism and clinical study[J].Signal Transduct Target Ther，2020，5（1）：209
    [22] AJIBADE A A，WANG Q F，CUI J，et al.TAK1 negatively regulates NF⁃κB and p38 MAP kinase activation in Gr⁃1+ CD11b+neutrophils[J].Immunity，2012，36（1）：43-54
    [23] LIU B，LIU Z Q，CHEN S S，et al.Mutant SF3B1 promotes AKT⁃and NF⁃κB⁃driven mammary tumorigenesis[J].J Clin Invest，2021，131（1）：e138315
    [24] YANG Q，ZHANG J，XU S，et al.Knockdown of PHF5A inhibits migration and invasion of HCC cells via eownreg-ulating NF⁃κB signaling[J].Biomed Res Int，2019，2019：1621854
    [25] WANG J，HUANG T J，MEI Y，et al.Novel long noncoding RNA LINC02820 augments TNF signaling pathway to remodel cytoskeleton and potentiate metastasis in esophageal squamous cell carcinoma[J].Cancer Gene Ther，2023，30（2）：375-387
    [26] LI C Z，XIE W Y，ROSENBLUM J S，et al.Somatic SF3B1 hotspot mutation in prolactinomas[J].Nat Commun，2020，11（1）：2506
    [27] GUO J，LI C Z，FANG Q Y，et al.The SF3B1 R625H mutation promotes prolactinoma tumor progression through aberrant splicing of DLG1[J].J Exp Clin Cancer Res，2022，41（1）：26
    [28] WANG H H，LIU F L，BAI C X，et al.PHF5A promotes proliferation and migration of non⁃small cell lung cancer-by regulating of PI3K/AKT pathway[J].Chin J Lung Cancer，2023，26（1）：10-16
    [29] ZHAN X，YAN C，ZHANG X，et al.Structures of the human pre-catalytic spliceosome and its precursor spliceo-some[J].Cell Res，2018，28：1129-1140
    [30] LIU K L，YIN Y W，LU B S，et al.E2F6/KDM5C promotes SF3A3 expression and bladder cancer progression through a specific hypomethylated DNA promoter[J].Cancer Cell Int，2022，22（1）：109
    [31] GUELFI S，HODIVALA⁃DILKE K，BERGERS G.Targeting the tumour vasculature：from vessel destruction to promotion[J].Nat Rev Cancer，2024，24（10）：655-675
    [32] FURUMAI R，UCHIDA K，KOMI Y，et al.Spliceostatin A blocks angiogenesis by inhibiting global gene expression including VEGF[J].Cancer Sci，2010，101（11）：2483-2489
    [33] LOO Y M，GALE M.Immune signaling by RIG⁃I⁃like receptors[J].Immunity，2011，34（5）：680-692
    [34] CHANG A Y，ZHOU Y J，IYENGAR S，et al.Modulation of SF3B1 in the pre⁃mRNA spliceosome induces a RIG⁃Ⅰ ⁃dependent type Ⅰ IFN response[J].J Biol Chem，2021，297（5）：101277
    [35] YOU H M，WANG L，MENG H W，et al.Pyroptosis：shedding light on the mechanisms and links with cancers[J].Front Immunol，2023，14：1290885
    [36] WARREN C F A，WONG⁃BROWN M W，BOWDEN N A.BCL ⁃ 2 family isoforms in apoptosis and cancer[J].Cell Death Dis，2019，10（3）：177
    [37] POPLI P，RICHTERS M M，CHADCHAN S B，et al.Splicing factor SF3B1 promotes endometrial cancer progression via regulating KSR2 RNA maturation[J].Cell Death Dis，2020，11（10）：842
    [38] WANG S R，LIU Y，XIAO H M，et al.Inhibition of SF3B1 improves the immune microenvironment through pyropto-sis and synergizes with αPDL1 in ovarian cancer[J].Cell Death Dis，2023，14（11）：775
    相似文献
    引证文献
    网友评论
    网友评论
    分享到微博
    发 布
引用本文

李建璋,张洁贞,周琳. U2snRNP：肿瘤发生发展中的关键介质[J].南京医科大学学报（自然科学版）,2025,(3):418-425

复制
分享
文章指标
  • 点击次数:7
  • 下载次数: 21
  • HTML阅读次数: 11
  • 引用次数: 0
历史
  • 收稿日期:2024-10-10
  • 在线发布日期: 2025-03-17

友情链接 Links

技术支持：北京勤云科技发展有限公司
关闭